**SUPPLEMENTAL MATERIAL**

**SUPPLEMENTAL FIGURE 1.** Patient Flow Chart

**SUPPLEMENTAL TABLE 1.** Baseline characteristics of patients with COVID-19 by AA race.

**SUPPLEMENTAL TABLE 2.** Univariable analysis for in-hospital mortality by baseline characteristics, home medications, initial vital signs, and initial labs.

**SUPPLEMENTAL TABLE 3.** Comparison of burden of comorbidities by published reports by COVID-19 centers and geographic location.

**SUPPLEMENTAL FIGURE 1.** Patient Flow Chart

*Legend:* AA – African American, EMR – electronic medical record

**SUPPLEMENTAL TABLE 1.** Baseline characteristics of patients with COVID-19 by AA race.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **All (n=689)** | **African-American (n=596)** | **Non African-American (n=93)** | **P** |
| **Age median (IQR)** | 55 (40-68) | 55 (41-68) | 51 (34-65) | **0.04** |
| **Age Category** |  |  |  | **0.02** |
| **<40** | 171 (24.8) | 137 (23.0) | 34 (36.6) | **<0.01** |
| **40-60** | 247 (35.9) | 220 (36.9) | 27 (29.0) | 0.14 |
| **>60** | 271 (39.3) | 239 (40.1) | 32 (34.4) | 0.3 |
| **Male** | 296 (43.0) | 245 (41.1) | 51 (54.8) | **0.01** |
| **Tobacco Use** | 171 (25.8) | 151 (26.1) | 20 (23.5) | 0.62 |
| **Obesity** |  |  |  |  |
| **BMI <30 kg/m2** | 261 (43.5) | 213 (40.7) | 48 (62.3) | **<0.001** |
| **BMI 30-40 kg/m2** | 234 (39.0) | 210 (40.2) | 24 (31.2) | 0.13 |
| **BMI >40 kg/m2** | 105 (17.5) | 100 (19.1) | 5 (6.5) | **0.01** |
| **Diabetes Mellitus** | 186 (30.6) | 174 (33.0) | 12 (15.0) | **0.001** |
| **HTN** | 331 (54.4) | 308 (58.3) | 23 (28.8) | **<0.001** |
| **Stroke/Cerebrovasc. Disease** | 36 (5.9) | 34 (6.4) | 2 (2.5) | 0.21 |
| **CKD (Stage III-VI)** | 72 (11.8) | 71 (13.5) | 1 (1.3) | **0.002** |
| **COPD** | 53 (8.7) | 51 (9.7) | 2 (2.5) | **0.03** |
| **Asthma** | 105 (17.3) | 95 (18.0) | 10 (12.5) | 0.23 |
| **Cancer** | 52 (8.6) | 46 (8.7) | 6 (7.5) | 0.72 |
| **CAD** | 90 (14.8) | 84 (15.9) | 6 (7.5) | **0.048** |
| **HF** | 62 (10.2) | 59 (11.2) | 3 (3.8) | **0.04** |
| **AF** | 44 (7.2) | 37 (7.0) | 7 (8.8) | 0.58 |
| ***Outpatient Medications*** | | | | |
| **ACEI** | 70 (13.5) | 64 (14.2) | 6 (9.0) | 0.25 |
| **ARB** | 57 (11.0) | 51 (11.3) | 6 (9.0) | 0.57 |
| **Anticoagulation** | 66 (12.7) | 58 (12.8) | 8 (11.9) | 0.84 |
| **Immunomodulator** | 85 (16.4) | 78 (17.3) | 7 (10.5) | 0.16 |
| **Antiviral** | 80 (15.4) | 70 (15.5) | 10 (14.9) | 0.91 |
| **Beta-Blocker** | 108 (20.8) | 101 (22.4) | 7 (10.5) | **0.03** |
| **Calcium channel blocker** | 103 (19.9) | 97 (21.5) | 6 (9.0) | **0.02** |
| **Antiplatelet** | 91 (17.5) | 84 (18.6) | 7 (10.5) | 0.1 |
| **NSAID** | 95 (18.3) | 90 (19.9) | 5 (7.5) | **0.01** |
| **Statin** | 115 (22.2) | 103 (22.8) | 12 (17.9) | 0.37 |
| **Diuretics** | 138 (26.6) | 126 (27.9) | 12 (17.9) | 0.09 |
| **Insulin** | 62 (12.0) | 57 (12.6) | 5 (7.5) | 0.23 |
| **Asthma-COPD inhaler** | 155 (29.9) | 138 (30.5) | 17 (25.4) | 0.39 |

*Table Legend:* BMI – Body Mass Index; HTN – hypertension; CKD – Chronic Kidney Disease; COPD – Chronic Obstructive Pulmonary Disease; CAD – Coronary Artery Disease; HF – Heart Failure; AF – Atrial Fibrillation; ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; NSAID – Non-steroidal Anti-inflammatory Drugs

**SUPPLEMENTAL TABLE 2.** Univariable analysis for in-hospital mortality by baseline characteristics, home medications, initial vital signs, and initial laboratory values.

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **OR** | **95% CI** | **p** |
| **Ferritin > 300 ng/mL** | 5.21 | (1.57-17.30) | **0.007** |
| **BUN > 20 mg/dL** | 4.72 | (2.34-9.51) | **<0.001** |
| **K > 5 mmol/L** | 4.01 | (1.68-9.60) | **0.002** |
| **Age > 60 years** | 3.55 | (1.70-7.41) | **0.001** |
| **AF** | 3.43 | (1.39-8.47) | **0.008** |
| **Troponin > 22 ng/L** | 3.36 | (1.73-6.52) | **<0.001** |
| **Cr > 1.4 mg/dL** | 3.15 | (1.66-5.97) | **<0.001** |
| **NT pro-BNP > 125 pg/mL** | 3.07 | (1.54-6.12) | **0.001** |
| **CK > 185 U/L** | 3.04 | (1.47-6.32) | **0.003** |
| **AST > 37 U/L** | 2.81 | (1.42-5.57) | **0.003** |
| **HCO3 < 23 mmol/L** | 2.59 | (1.29-5.21) | **0.007** |
| **Tobacco Use** | 2.53 | (1.33-4.80) | **0.005** |
| **CAD** | 2.50 | (1.18-5.31) | **0.02** |
| **Diuretic** | 2.34 | (1.09-5.01) | **0.03** |
| **ARB** | 2.04 | (0.81-5.12) | 0.13 |
| **CKD (Stage III-VI)** | 1.76 | (0.79-3.92) | 0.16 |
| **COPD** | 1.76 | (0.67-4.60) | 0.25 |
| **Antiplatelet** | 1.76 | (0.78-3.97) | 0.17 |
| **O2 Sat < 95 (%)** | 1.67 | (0.89-3.15) | 0.11 |
| **RR > 20** | 1.44 | (0.77-2.69) | 0.26 |
| **Male** | 1.42 | (0.76-2.67) | 0.27 |
| **Diabetes Mellitus** | 1.25 | (0.61-2.56) | 0.54 |
| **HR > 100** | 1.25 | (0.67-2.35) | 0.48 |
| **HTN** | 1.23 | (0.55-2.75) | 0.61 |
| **Statin** | 1.16 | (0.52-2.59) | 0.72 |
| **Temperature > 99F** | 1.10 | (0.53-2.28) | 0.80 |
| **HF** | 1.03 | (0.40-2.63) | 0.95 |
| **Cancer** | 0.95 | (0.31-2.85) | 0.92 |
| **Anticoagulation** | 0.94 | (0.34-2.58) | 0.90 |
| **Insulin** | 0.91 | (0.33-2.51) | 0.86 |
| **Stroke** | 0.90 | (0.26-3.14) | 0.87 |
| **Inhaler** | 0.83 | (0.34-2.03) | 0.69 |
| **SBP >130 mmHg** | 0.67 | (0.35-1.26) | 0.21 |
| **ACEI** | 0.59 | (0.20-1.77) | 0.35 |
| **African-American** | 0.44 | (0.19-1.05) | 0.07 |
| **Beta-Blocker** | 0.38 | (0.13-1.14) | 0.08 |
| **BMI >40 kg/m2** | 0.33 | (0.12-0.97) | **0.044** |
| **Asthma** | 0.32 | (0.07-1.37) | 0.12 |

*Table Legend:* BMI – Body Mass Index; HTN – hypertension; CKD – Chronic Kidney Disease; COPD – Chronic Obstructive Pulmonary Disease; CAD – Coronary Artery Disease; HF – Heart Failure; AF – Atrial Fibrillation; ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; HR – Heart Rate; SBP – Systolic Blood Pressure; RR – Respiratory Rate; NT pro-BNP – N-terminal pro-brain natriuretic peptide; CK – Creatine Kinase; K – Potassium; HCO3 – Bicarbonate; BUN – Blood Urea Nitrogen; Cr – Creatinine; AST – Aspartate Aminotransferase

**SUPPLEMENTAL TABLE 3.** Comparison of burden of comorbidities by published reports by COVID-19 centers and geographic location.

*Table Legend:* Shaded boxes are those with the highest incidence of the characteristic or comorbidity noted. AA – African American; DM – Diabetes mellitus; HTN – Hypertension; CVD/CAD – Cardiovascular disease or coronary artery disease; COPD – Chronic obstructive pulmonary disease; CKD – Chronic kidney disease; Vent – Invasive ventilation; SNF – Skilled nursing facility; ICU – Intensive care unit

**Table References:**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Study End** | **Population** | **Location** | **N** | **Age** | **Male** | **AA** | **Obesity** | **Tob-baco** | **DM** | **HTN** | **CVD/ CAD** | **HF** | **COPD** | **CKD** | **Asth-ma** | **Can-cer** | **Vent** | **Death** |
| Wang et al1 | 1/28/2020 | Inpatient | China | 138 | 56 | 54% |  |  |  | 10% | 31% | 15% |  | 3% | 3% |  | 7% |  | 4% |
| Guan et al2 | 1/29/2020 | Inpatient | China | 1099 | 47 | 58% |  |  | 13% | 7% | 15% | 3% |  | 1% | 1% |  | 1% | 2% | 1% |
| Zhou et al3 | 1/31/2020 | Inpatient | China | 191 | 56 | 62% |  |  | 6% | 19% | 30% | 8% |  | 3% | 1% |  | 1% | 17% | 28% |
| Zhang et al4 | 2/3/2020 | Inpatient | China | 140 | 57 | 51% |  |  | 1% | 12% | 30% | 5% |  | 1% | 1% |  |  |  |  |
| Shi et al5 | 2/10/2020 | Inpatient | China | 416 | 64 | 49% |  |  |  | 14% | 31% | 11% | 4% | 3% | 3% |  | 2% | 8% | 14% |
| Wu et al6 | 2/11/2020 | In/Out-Patient | China | 44672 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2% |
| Guo et al7 | 2/23/2020 | Inpatient | China | 187 | 58 | 49% |  |  |  | 15% | 33% | 11% | 4% | 2% | 3% |  | 7% | 24% | 23% |
| Bhatraju et al8 | 3/9/2020 | ICU only | Seattle | 24 | 64 | 63% |  |  |  | 58% |  |  |  | 4% | 21% |  | 0% | 75% | 50% |
| Grasselli et al9 | 3/18/2020 | ICU only | Lombardy | 1591 | 63 | 82% |  |  |  | 17% | 49% | 21% |  | 4% | 3% |  | 8% | 88% | 26% |
| McMichael et al9 | 3/18/2020 | SNF | Washington | 167 | 72 | 33% |  | 22% |  | 23% | 44% | 41% |  |  | 26% |  | 9% |  | 21% |
| Goyal et al10 | 3/27/2020 | Inpatient | New York | 393 | 62 | 61% |  | 36% | 5% | 25% | 50% | 14% |  | 5% |  | 13% |  | 5% | 10% |
| Gold et al11 | 3/30/2020 | Inpatient | Georgia | 305 | 60 | 49% | 83% | 13% | 5% | 40% | 68% | 26% | 11% | 20% | 5% | 11% | 4% | 30% | 17% |
| Myers et al12 | 3/31/2020 | Inpatient | California | 377 | 61 | 56% |  |  |  | 31% | 44% |  | 6% |  | 13% |  | 5% | 29% | 16% |
| Petrilli et al13 | 4/2/2020 | In/Out-Patient | New York | 4103 | 52 | 50% | 16% | 27% | 5% | 15% | 24% | 6% | 3% |  | 5% |  | 5% |  | 15% |
| Richardson et al14 | 4/4/2020 | Inpatient | New York | 5700 | 63 | 60% | 23% | 42% |  | 34% | 57% | 11% | 7% | 5% | 9% | 9% | 6% | 12% | 21% |
| Price et al15 | 4/11/2020 | In/Out-Patient | Louisiana | 3481 | 54 | 40% | 70% | 50% |  | 16% | 31% | 4% | 4% | 2% | 8% | 4% | 5% | 26% | 24% |
| Lala et al16 | 4/12/2020 | Inpatient | New York | 2736 | 66 | 60% | 26% |  |  | 26% | 39% | 17% | 10% | 6% | 10% | 8% | 7% |  |  |
| **PRESENT STUDY** | 4/16/2020 | Inpatient | Chicago | 356 | 61 | 48% | 90% | 58% | 33% | 42% | 70% | 22% | 17% | 12% | 20% | 15% | 12% | 16% | 13% |

1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.

2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.

3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.

4. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.

5. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020.

6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.

7. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020.

8. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med*. 2020.

9. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020.

10. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. *N Engl J Med*. 2020.

11. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(18):545-550.

12. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. *JAMA*. 2020.

13. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City. *medRxiv*. 2020. https://doi.org/10.1101/2020.04.08.20057794

14. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020.

15. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *N Engl J Med.* 2020.

16. Lala A, Johnson KW, Russak AJ, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. *medRxiv*. 2020. https://doi.org/10.1101/2020.04.20.2007